Sklar Kirsh Advises Catalent on Acquisition of Pharmatek Laboratories

News provided by

Oct 05, 2016, 01:00 ET

LOS ANGELES, Oct. 5, 2016 /PRNewswire/ -- Catalent, Inc., the New Jersey-based leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, has acquired Pharmatek Laboratories, Inc., a San Diego-based specialist in drug development and clinical manufacturing.

Scott Ehrlich, Simone Collins and Yulia Terentyeva of Sklar Kirsh LLP led the deal team representing Catalent.

"We are proud to have assisted Catalent with its expansion in early drug development services and technologies," said Ehrlich, a partner in Sklar Kirsh's Corporate Group.

Pharmatek was represented by Cooley LLP.

About Sklar Kirsh
Sklar Kirsh LLP counsels privately held and public companies, family offices, growing businesses, and high net worth individuals on legal and business matters that arise at all stages of the business and real estate life cycle, including mergers and acquisitions, purchase and sale agreements, equity and debt financings, fund formation, leasing, corporate governance, tax, executive compensation and employment arrangements, and dispute resolution. For more information, visit www.SklarKirsh.com.

SOURCE Sklar Kirsh LLP